Samantha Vieira
Directeur des opérations chez Anjarium Biosciences AG
Profil
Samantha Vieira is currently the Chief Operating Officer at Anjarium Biosciences AG since 2022.
Prior to this, she worked as the Executive Director-Global Product Development at Biogen, Inc. from 2019 to 2021.
Postes actifs de Samantha Vieira
| Sociétés | Poste | Début |
|---|---|---|
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Directeur des opérations | 12/07/2022 |
Anciens postes connus de Samantha Vieira
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/08/2021 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |